Monitoring Fruzaqla treatment in adults with metastatic colorectal cancer in South Korea

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational, non-interventional study will enroll adults in South Korea who start or are receiving Fruzaqla for metastatic colorectal cancer and will collect adverse event data while patients are treated according to the approved label. Investigators at Yonsei University Hospital will record all adverse events and serious adverse events and estimate the proportion of patients experiencing these events. Key exclusions include patients with contraindications to Fruzaqla, pregnant or breastfeeding women, and those participating in other interventional mCRC trials. The study is sponsored by Takeda to provide postmarketing safety data specific to the Korean population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age greater than or equal to (\>=)18 years.
* Participants who are initiate treatment or will be treated with Fruzaqla according to the approved label of South Korea.
* Participant voluntarily consent to participate in the study.

Exclusion criteria:

* Participants for whom Fruzaqla is contraindicated or those with risks that should avoid starting Fruzaqla, as per the product label.
* Participants actively participating in other interventional clinical trial(s) on mCRC treatments.
* Pregnant or breastfeeding women.

Where it's running

• Yonsei University Hospital
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Takeda Contact
• Email: medinfoUS@takeda.com
• Phone: +1-877-825-3327

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• DSP107 plus atezolizumab versus fruquintinib for advanced colorectal cancer

  This test will see if giving DSP107 together with atezolizumab works better and is as safe as fruquintinib for adults with advanced microsatellite-stable colorectal cancer who have already tried standard treatments.

  Recruiting at 18 sites Phase 2 Kahr Medical · Aurora, Colorado and 17 other locations · NCT07235293

• Fruquintinib plus FOLFIRI for second-line metastatic colorectal cancer

  This study will test whether adding fruquintinib to FOLFIRI helps people with metastatic colorectal cancer who progressed after first-line FOLFOX plus bevacizumab.

  Recruiting at 14 sites Phase 2 SCRI Development Innovations, LLC · Denver, Colorado and 13 other locations · NCT07011576

• Fruquintinib with or without TAS-102 for refractory metastatic colorectal cancer

  This trial tests whether adding TAS-102 (Lonsurf) to fruquintinib helps people with microsatellite-stable, advanced or metastatic colorectal cancer that no longer responds to standard chemotherapy.

  Recruiting at 13 sites Phase 2 Criterium, Inc. · New Haven, Connecticut and 12 other locations · NCT06992258

• Evaluating fruquintinib's safety in minority groups with advanced colorectal cancer

  This study is testing if fruquintinib is safe for Black and Hispanic adults with advanced colorectal cancer who have already had treatment.

  Recruiting at 32 sites Phase 4 Takeda · Birmingham, Alabama and 44 other locations · NCT06562543

• Combining fruquintinib with HAI-FOLFOX for treating refractory colorectal cancer

  This study tests whether combining a new drug called fruquintinib with a specific chemotherapy method can help people with colorectal cancer that hasn't responded to other treatments live longer and feel better.

  Recruiting Phase 2/3 Sun Yat-sen University · Guangzhou, Guangdong · NCT06441565

• Combining Fruquintinib, Regorafenib, and Sintilimab with Radiotherapy for Advanced Colorectal Cancer

  This study is testing a new combination of three cancer drugs with or without radiation to see if it helps people with advanced colorectal cancer who have already tried other treatments.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT06356584

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.